A Phase 1/2 interventional study of Ranibizumab in Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD), sponsored by Novartis. Completed at 1 site in Japan. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2011-02-24.
Sponsored by Novartis · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing ranibizumab in Choroidal Neovascularization — none open to participants now, none under way, none of them phase 3. Ranibizumab · Choroidal Neovascularization.
Among the 45 studies testing ranibizumab in Choroidal Neovascularization, this one is the 20th largest by enrollment, is one of 4 that started in 2005, is one of 4 in phase 1/2, and was the 2nd registered.
214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.
Browse Choroidal Neovascularization studies →None of the 45 studies testing ranibizumab in Choroidal Neovascularization is open now. The open studies under Choroidal Neovascularization, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 6 Choroidal Neovascularization studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 15 · Phase 3 12 · Phase 4 12
First in 2005; this study’s year is marked. 4 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 88 is above the median of 56 across 160 interventional studies indexed under Choroidal Neovascularization.
Median enrollment 62 across the 45 interventional studies. Of the 44 that completed or were terminated, 23 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 45 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
29 studies in Choroidal Neovascularization by Novartis: none open now, none under way, none of them phase 3. Of 29 finished, 22 (76%) have results posted.
Among the 29 studies in Choroidal Neovascularization by Novartis, this one is the 24th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2005, is the only one in phase 1/2, and was the 3rd registered.
Novartis’s Choroidal Neovascularization studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 45 studies testing ranibizumab in Choroidal Neovascularization, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 29 in Choroidal Neovascularization:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Open-label Multicenter, Phase I/II Study comprising three phases (single dose, multiple dose and extension phase), Assessing the Safety and Efficacy of Ranibizumab (RFB002) in Japanese Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD).
The safety and tolerability of single intravitreal injections of ranibizumab was evaluated in patients enrolled in the single dose phase (Group A). Patients who successfully completed the single dose phase (i.e. did not experience a grade-3 targeted adverse event) could enter the multiple dose phase and receive ranibizumab injections for an additional 11 months. Simultaneously, the multiple dose phase was initiated in two parallel dose groups of additional patients (Group B), who received ranibizumab injections for 12 months. After patients in Group A and Group B had completed the multiple dose phase, all patients who provided written consent and were considered eligible based on the inclusion and exclusion criteria of the extension phase had the opportunity to continue on study treatment with the individualized flexible treatment regimen guided by monthly acuity scores and other ophthalmic examinations until approval of ranibizumab in Japan.
Inclusion Criteria
Exclusion Criteria
Extension Phase
Inclusion criteria:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the single dose phase, all patients randomized in Group A received a single intravitreal injection of 0.3 mg of ranibizumab into the study eye. Those patients who successfully completed this phase entered the multiple dose phase, where they received an intravitreal injection of 0.3 mg of ranibizumab once a month for an additional 11 months. Subsequently patients enrolling in the extension phase received an intravitreal injection of 0.3 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.70 years.
Drug: Ranibizumab
In the single dose phase, all patients randomized in Group A received a single intravitreal injection of 0.5 mg of ranibizumab into the study eye. Those patients who successfully completed this phase entered the multiple dose phase, where they received an intravitreal injection of 0.5 mg of ranibizumab once a month for an additional 11 months. Subsequently Group A patients enrolling in the extension phase received an intravitreal injection of 0.5 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.93 years.
Drug: Ranibizumab
Group B patients received a total of 12 monthly intravitreal injections of 0.3 mg of ranibizumab into the study eye in the multiple dose phase of the study. Group B patients who enrolled in the extension phase received an intravitreal injection of 0.3 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.45 years.
Drug: Ranibizumab
Group B patients received a total of 12 monthly intravitreal injections of 0.5 mg of ranibizumab into the study eye in the multiple dose phase of the study. Group B patients who enrolled in the extension phase received an intravitreal injection of 0.5 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.36 years.
Drug: Ranibizumab
Ranibizumab was administered by intravitreal injection in the study eye. Intravitreal injection was performed by the investigator following slitlamp examination.
Also known as: Lucentis
Mean Change From Baseline in the Best Corrected Visual Acuity Score of the Study Eye at Month 6 in Group B
The efficacy assessment was based on Group B patients. Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 2 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a starting test distance of 2 meters. The BCVA score is the number of letters read correctly by the patient, hence an increase in score indicates improvement in acuity.
Time frame: Baseline and Month 6
Mean Change From Baseline in the Best Corrected Visual Acuity Score of the Study Eye at Month 12 in Group B
The efficacy assessment was based on Group B patients. BCVA was assessed during all study visits using best correction determined from protocol refraction and ETDRS-like visual acuity testing charts at a starting test distance of 2 meters. The BCVA score is the number of letters read correctly by the patient, hence an increase in score indicates improvement in acuity.
Time frame: Baseline and Month 12
Categorical Analysis of Best Corrected Visual Acuity of the Study Eye at Month 6 and Month 12 in Group B
BCVA measurements were taken in a sitting position using best correction determined from protocol refraction and ETDRS-like visual acuity testing charts at a starting test distance of 2 meters.
Time frame: Baseline, Month 6 and Month 12
Extension Phase: Mean Change From Month 12 (Start of Extension Phase) in Best Corrected Visual Acuity Score of the Study Eye at Last Visit of Extension Phase in Group B.
Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 2 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a starting test distance of 2 meters. The BCVA score is the number of letters read correctly by the patient, hence an increase in score indicates improvement in acuity.
Time frame: Month 12 (start of extension phase) and last visit of extension phase. Duration in the extension phase varied depending on the study entry. The mean duration of treatment was 1.45 years in the 0.3 mg group and 1.36 years in the 0.5 mg dose group.
Extension Phase: Categorical Analysis of Best Corrected Visual Acuity of the Study Eye at Last Visit of Extension Phase in Group B
BCVA measurements were taken in a sitting position using best correction determined from protocol refraction and ETDRS-like visual acuity testing charts at a starting test distance of 2 meters. The following categories were evaluated: * Participants with a BCVA score loss of fewer than 15 letters from baseline at Last Visit * Participants with a BCVA score loss of 30 or more letters from baseline at Last Visit * Participants with a BCVA score gain of 15 or more letters from baseline at Last Visit * Participants with a BCVA score of less than 34 letters at Last Visit
Time frame: Baseline and last visit of extension phase - Duration in the extension phase varied depending on the study entry. The mean duration of treatment was 1.45 years in the 0.3 mg group and 1.36 years in the 0.5 mg dose group.
Mean Change From Baseline in Total Area of Choroidal Neovascularization of the Study Eye in Group B
Choroidal Neovascularization was assessed by fluorescein angiography in conjunction with color fundus photography. Analysis was performed by the central reading center. The area of Choroidal Neovascularization is expressed as Macular Photocoagulation Study standard Disc Areas (DA; equivalent to 2.54 mm\^2 on the retina).
Time frame: Baseline, Months 3, 6, 9 and 12
Mean Change From Baseline in Total Area of Leakage From CNV Plus Staining of Retinal Pigment Epithelium of the Study Eye in Group B
Area of leakage from CNV plus staining of retinal pigment epithelium was assessed by fluorescein angiography in conjunction with color fundus photography. Analysis was performed by the central reading center. The total area is expressed as Macular Photocoagulation Study standard Disc Areas (DA; equivalent to 2.54 mm\^2 on the retina).
Time frame: Baseline, Months 3, 6, 9 and 12
Percentage of Participants in Group B With Absence of Leakage in the Study Eye at Month 3, 6, 9 and 12.
Area of leakage was assessed by fluorescein angiography in conjunction with color fundus photography. Analysis was performed at the central reading center.
Time frame: Months 3, 6, 9 and 12
Mean Change From Baseline in Foveal Retinal Thickness of the Study Eye in Group B
Foveal retinal thickness was assessed by Optical Coherence Tomography (OCT) at a subset of the study sites and was analyzed by the central reading center.
Time frame: Baseline, Months 3, 6, 9 and 12
Mean Change From Baseline in Total Retinal Volume of the Study Eye in Group B
Total retinal volume was assessed by Optical Coherence tomography (OCT) at a subset of the study sites and was analyzed by the central reading center.
Time frame: Baseline, Months 3, 6, 9 and 12
| Milestone | Group A: Ranibizumab 0.3 mg | Group A: Ranibizumab 0.5 mg | Group B: Ranibizumab 0.3 mg | Group B: Ranibizumab 0.5 mg |
|---|---|---|---|---|
| Started | 6 | 6 | 0 | 0 |
| Completed | 6 | 6 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Group A: Ranibizumab 0.3 mg | Group A: Ranibizumab 0.5 mg | Group B: Ranibizumab 0.3 mg | Group B: Ranibizumab 0.5 mg |
|---|---|---|---|---|
| Started | 5 | 6 | 35 | 41 |
| Completed | 4 | 6 | 31 | 37 |
| Not completed | 1 | 0 | 4 | 4 |
| Withdrew: Adverse event | 1 | 0 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 2 |
| Withdrew: Death | 0 | 0 | 1 | 1 |
| Milestone | Group A: Ranibizumab 0.3 mg | Group A: Ranibizumab 0.5 mg | Group B: Ranibizumab 0.3 mg | Group B: Ranibizumab 0.5 mg |
|---|---|---|---|---|
| Started | 3 | 6 | 28 | 33 |
| Completed | 1 | 6 | 22 | 21 |
| Not completed | 2 | 0 | 6 | 12 |
| Withdrew: Adverse event | 0 | 0 | 2 | 2 |
| Withdrew: Condition no longer requires study drug | 2 | 0 | 2 | 7 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 3 |
The efficacy assessment was based on Group B patients. Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 2 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a starting test distance of 2 meters. The BCVA score is the number of letters read correctly by the patient, hence an increase in score indicates improvement in acuity.
| Number of Letters | Group B: Ranibizumab 0.3 mg | Group B: Ranibizumab 0.5 mg |
|---|---|---|
| Baseline | 47.6 ± 11.82 | 48.1 ± 10.75 |
| Month 6 | 55.7 ± 13.16 | 57.1 ± 14.99 |
| Change from Baseline | 8.1 ± 12.65 | 9.0 ± 9.62 |
The efficacy assessment was based on Group B patients. BCVA was assessed during all study visits using best correction determined from protocol refraction and ETDRS-like visual acuity testing charts at a starting test distance of 2 meters. The BCVA score is the number of letters read correctly by the patient, hence an increase in score indicates improvement in acuity.
| Number of Letters | Group B: Ranibizumab 0.3 mg | Group B: Ranibizumab 0.5 mg |
|---|---|---|
| Baseline | 47.6 ± 11.82 | 48.1 ± 10.75 |
| Month 12 | 57.1 ± 12.91 | 58.6 ± 15.44 |
| Change from Baseline | 9.5 ± 12.79 | 10.5 ± 11.14 |
BCVA measurements were taken in a sitting position using best correction determined from protocol refraction and ETDRS-like visual acuity testing charts at a starting test distance of 2 meters.
| Participants | Group B: Ranibizumab 0.3 mg | Group B: Ranibizumab 0.5 mg |
|---|---|---|
| Loss of < 15 letters from Baseline at month 6 | 34 | 41 |
| Loss of < 15 letters from Baseline at month 12 | 34 | 41 |
| Gain of ≥15 letters from Baseline at month 6 | 12 | 10 |
| Gain of ≥15 letters from Baseline at month 12 | 13 | 13 |
| Loss of ≥30 letters from Baseline at month 6 | 0 | 0 |
| Loss of ≥30 letters from Baseline at month 12 | 0 | 0 |
| Visual acuity < 34 letters at Month 6 | 2 | 2 |
| Visual acuity < 34 letters at Month 12 | 2 | 1 |
Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 2 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a starting test distance of 2 meters. The BCVA score is the number of letters read correctly by the patient, hence an increase in score indicates improvement in acuity.
| Letters | Group B: Ranibizumab 0.3 mg | Group B: Ranibizumab 0.5 mg |
|---|---|---|
| Baseline | 47.9 ± 12.59 | 50.0 ± 10.38 |
| Month 12 | 59.1 ± 11.69 | 59.8 ± 15.07 |
| Last visit | 55.4 ± 17.14 | 57.6 ± 15.36 |
| Change from Month 12 | -3.6 ± 14.82 | -2.2 ± 7.92 |
BCVA measurements were taken in a sitting position using best correction determined from protocol refraction and ETDRS-like visual acuity testing charts at a starting test distance of 2 meters. The following categories were evaluated: * Participants with a BCVA score loss of fewer than 15 letters from baseline at Last Visit * Participants with a BCVA score loss of 30 or more letters from baseline at Last Visit * Participants with a BCVA score gain of 15 or more letters from baseline at Last Visit * Participants with a BCVA score of less than 34 letters at Last Visit
| Participants | Group B: Ranibizumab 0.3 mg | Group B: Ranibizumab 0.5 mg |
|---|---|---|
| Loss of < 15 letters from Baseline | 24 | 32 |
| Gain of ≥15 letters from Baseline | 9 | 9 |
| Loss of ≥30 letters from Baseline | 1 | 1 |
| Visual acuity < 34 letters | 3 | 1 |
Choroidal Neovascularization was assessed by fluorescein angiography in conjunction with color fundus photography. Analysis was performed by the central reading center. The area of Choroidal Neovascularization is expressed as Macular Photocoagulation Study standard Disc Areas (DA; equivalent to 2.54 mm\^2 on the retina).
| disc areas | Group B: Ranibizumab 0.3 mg | Group B: Ranibizumab 0.5 mg |
|---|---|---|
| Baseline [N=35, 41] | 2.11 ± 1.10 | 2.03 ± 1.66 |
| Mean change from Baseline at Month 3 [N=34, 40] | -0.10 ± 0.95 | 0.13 ± 0.75 |
| Mean change from Baseline at Month 6 [N=34, 40] | -0.15 ± 0.97 | 0.04 ± 0.76 |
| Mean change from Baseline at Month 9 [N=34, 40] | -0.23 ± 0.97 | 0.21 ± 0.90 |
| Mean change from Baseline at Month 12 [N=34, 40] | -0.16 ± 1.01 | 0.23 ± 1.08 |
Area of leakage from CNV plus staining of retinal pigment epithelium was assessed by fluorescein angiography in conjunction with color fundus photography. Analysis was performed by the central reading center. The total area is expressed as Macular Photocoagulation Study standard Disc Areas (DA; equivalent to 2.54 mm\^2 on the retina).
| disc areas | Group B: Ranibizumab 0.3 mg | Group B: Ranibizumab 0.5 mg |
|---|---|---|
| Baseline [N=35, 41] | 2.31 ± 1.17 | 2.49 ± 1.54 |
| Mean change from Baseline at Month 3 [N=34, 40] | -0.76 ± 0.85 | -0.74 ± 1.21 |
| Mean change from Baseline at Month 6 [N=34, 40] | -1.21 ± 0.87 | -1.10 ± 1.19 |
| Mean change from Baseline at Month 9 [N=34, 40] | -1.39 ± 1.02 | -1.26 ± 1.45 |
| Mean change from Baseline at Month 12 [N=34, 40] | -1.50 ± 1.08 | -1.39 ± 1.48 |
Area of leakage was assessed by fluorescein angiography in conjunction with color fundus photography. Analysis was performed at the central reading center.
| Percentage of participants | Group B: Ranibizumab 0.3 mg | Group B: Ranibizumab 0.5 mg |
|---|---|---|
| Month 3 | 2.9 | 7.5 |
| Month 6 | 8.8 | 15.0 |
| Month 9 | 26.5 | 25.0 |
| Month 12 | 35.3 | 35.0 |
Foveal retinal thickness was assessed by Optical Coherence Tomography (OCT) at a subset of the study sites and was analyzed by the central reading center.
| micrometers | Group B: Ranibizumab 0.3 mg | Group B: Ranibizumab 0.5 mg |
|---|---|---|
| Baseline [N=28, 30] | 336.7 ± 195.3 | 370.7 ± 171.9 |
| Mean change from Baseline at Month 3 [N=27, 29] | -124.4 ± 141.6 | -195.6 ± 187.5 |
| Mean change from Baseline at Month 6 [N=26, 28] | -142.9 ± 199.3 | -225.6 ± 192.2 |
| Mean change from Baseline at Month 9 [N=26, 27] | -188.4 ± 190.1 | -245.4 ± 203.1 |
| Mean change from Baseline at Month 12 [N=26, 26] | -194.0 ± 199.8 | -257.8 ± 209.8 |
Total retinal volume was assessed by Optical Coherence tomography (OCT) at a subset of the study sites and was analyzed by the central reading center.
| micrometers | Group B: Ranibizumab 0.3 mg | Group B: Ranibizumab 0.5 mg |
|---|---|---|
| Baseline [N=11, 11] | 7.23 ± 0.84 | 7.36 ± 0.97 |
| Mean change from Baseline at Month 3 [N=7, 7] | -0.78 ± 0.74 | -0.67 ± 0.71 |
| Mean change from Baseline at Month 6 [N=6, 6] | -0.52 ± 0.60 | -0.92 ± 0.96 |
| Mean change from Baseline at Month 9 [N=4, 5] | -0.48 ± 0.03 | -0.28 ± 0.83 |
| Mean change from Baseline at Month 12 [N=6, 6] | -0.95 ± 1.14 | -0.42 ± 0.67 |
Collected over The timeframe for the Core Phase (Single and Multiple Dose Phases) was 12 months. For the Extension Phase adverse event data was collected from Month 12 through to the Last Visit (the maximum time on study was 35 months total).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Core Group A+B: Ranibizumab 0.3 mg | — | 5/41 (12.2%) | 38/41 (92.7%) |
| Core Group A+B: Ranibizumab 0.5 mg | — | 8/47 (17%) | 43/47 (91.5%) |
| Extension Group A+B: Ranibizumab 0.3 mg | — | 5/31 (16.1%) | 27/31 (87.1%) |
| Extension Group A+B: Ranibizumab 0.5 mg | — | 8/39 (20.5%) | 28/39 (71.8%) |
| Event | Core Group A+B: Ranibizumab 0.3 mg | Core Group A+B: Ranibizumab 0.5 mg | Extension Group A+B: Ranibizumab 0.3 mg | Extension Group A+B: Ranibizumab 0.5 mg |
|---|---|---|---|---|
| Visual acuity reduced transiently (Study eye)Eye disorders | 0/41 | 2/47 | 0/31 | 0/39 |
| Overdose (Study eye)Injury, poisoning and procedural complications | 0/41 | 2/47 | 0/31 | 0/39 |
| Intraocular pressure increased (Study eye)Investigations | 0/41 | 2/47 | 0/31 | 0/39 |
| Glaucomatocyclitic crises (Study eye)Eye disorders | 0/41 | 0/47 | 1/31 | 0/39 |
| Macular degeneration (Study eye)Eye disorders | 0/41 | 0/47 | 1/31 | 0/39 |
| Retinal detachment (Study eye)Eye disorders | 0/41 | 0/47 | 1/31 | 0/39 |
| Vitreous haemorrhage (Study eye)Eye disorders | 0/41 | 0/47 | 1/31 | 0/39 |
| EnteroceleGastrointestinal disorders | 0/41 | 0/47 | 1/31 | 0/39 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/41 | 0/47 | 1/31 | 0/39 |
| Cerebral infarctionNervous system disorders | 0/41 | 0/47 | 1/31 | 1/39 |
| Event | Core Group A+B: Ranibizumab 0.3 mg | Core Group A+B: Ranibizumab 0.5 mg | Extension Group A+B: Ranibizumab 0.3 mg | Extension Group A+B: Ranibizumab 0.5 mg |
|---|---|---|---|---|
| Conjunctival haemorrhage (Study eye)Eye disorders | 30/41 | 28/47 | 13/31 | 14/39 |
| Retinal haemorrhage (Study eye)Eye disorders | 12/41 | 5/47 | 9/31 | 10/39 |
| NasopharyngitisInfections and infestations | 7/41 | 10/47 | 6/31 | 9/39 |
| Eye pain (Study eye)Eye disorders | 9/41 | 10/47 | 2/31 | 0/39 |
| Conjunctival hyperaemia (Study eye)Eye disorders | 8/41 | 8/47 | 2/31 | 1/39 |
| Retinal haemorrhage (Fellow eye)Eye disorders | 3/41 | 5/47 | 6/31 | 2/39 |
| Punctate keratitis (Study eye)Eye disorders | 7/41 | 4/47 | 1/31 | 1/39 |
| HypertensionVascular disorders | 3/41 | 1/47 | 4/31 | 1/39 |
| Retinal detachment (Study eye)Eye disorders | 5/41 | 2/47 | 2/31 | 5/39 |
| Intraocular pressure increased (Study eye)Investigations | 2/41 | 6/47 | 2/31 | 4/39 |
| Age, Customized(Participants) | Group A: Ranibizumab 0.3 mg | Group A: Ranibizumab 0.5 mg | Group B: Ranibizumab 0.3 mg | Group B: Ranibizumab 0.5 mg | Total |
|---|---|---|---|---|---|
| 50 to <65 years | 2 | 0 | 8 | 10 | 20 |
| 65 to <75 years | 2 | 4 | 16 | 13 | 35 |
| 75 to <85 years | 2 | 2 | 10 | 15 | 29 |
| >= 85 years | 0 | 0 | 1 | 3 | 4 |
| Age, Customized(Participants) | Group A: Ranibizumab 0.3 mg | Group A: Ranibizumab 0.5 mg | Group B: Ranibizumab 0.3 mg | Group B: Ranibizumab 0.5 mg | Total |
|---|---|---|---|---|---|
| 50 to <65 years | 1 | 0 | 7 | 10 | 18 |
| 65 to <75 years | 1 | 4 | 14 | 10 | 29 |
| 75 to <85 years | 1 | 2 | 6 | 12 | 21 |
| >= 85 years | 0 | 0 | 1 | 1 | 2 |
| Sex: Female, Male(Participants) | Group A: Ranibizumab 0.3 mg | Group A: Ranibizumab 0.5 mg | Group B: Ranibizumab 0.3 mg | Group B: Ranibizumab 0.5 mg | Total |
|---|---|---|---|---|---|
| Female | 1 | 1 | 9 | 8 | 19 |
| Male | 5 | 5 | 26 | 33 | 69 |
| Gender(participants) | Group A: Ranibizumab 0.3 mg | Group A: Ranibizumab 0.5 mg | Group B: Ranibizumab 0.3 mg | Group B: Ranibizumab 0.5 mg | Total |
|---|---|---|---|---|---|
| Female | 0 | 1 | 9 | 5 | 15 |
| Male | 3 | 5 | 19 | 28 | 55 |
The record gives a start of Apr 2005, a primary completion of Mar 2007 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 3 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab
Choroidal Neovascularization →